MEDICA S.P.A.

Their core work

MEDICA S.P.A. is an Italian medical technology company based in Medolla that participates in the EU Graphene Flagship, contributing to the translation of graphene and 2D materials into practical applications. Their involvement spans biomedical technologies, composite materials, sensors, and energy applications — suggesting they bring industrial manufacturing capability and domain expertise in healthcare products to advanced materials research. Within the Flagship, they appear to serve as an industry partner helping bridge the gap between laboratory-scale graphene research and commercial product development, particularly through pilot line activities.

What they specialise in

How they've shifted over time

MEDICA's early H2020 involvement (2018) was broad and exploratory, touching graphene applications across composites, energy, electronics, photonics, sensors, and biomedical technologies through GrapheneCore2. By 2020, their focus sharpened significantly toward 2D materials and pilot line manufacturing, reflecting a natural progression from basic research participation to industrialization. This shift from wide-ranging application exploration to production-oriented work mirrors the Graphene Flagship's own maturation trajectory.

MEDICA is moving from research participation toward industrial-scale production of graphene-based products, making them increasingly relevant for partners seeking manufacturing and scale-up capabilities.

How they like to work

MEDICA operates exclusively as a participant in very large consortia — all three projects are part of the Graphene Flagship, which involves hundreds of partners across Europe. With 219 unique consortium partners across 21 countries, their network is vast but largely inherited from the Flagship structure rather than built through independent project selection. This suggests they are a trusted industry contributor within the Flagship ecosystem, valued for their specific manufacturing or application expertise rather than for leading research agendas.

Through the Graphene Flagship, MEDICA has connections to 219 partners across 21 countries, giving them one of the broadest contact networks in European advanced materials research. However, this network is consortium-inherited rather than independently built.

What sets them apart

MEDICA brings an unusual combination: a medical technology company deeply embedded in Europe's largest materials science initiative. While most Graphene Flagship industrial partners come from electronics or chemicals, MEDICA's healthcare background offers a distinctive pathway for translating 2D materials into biomedical products. Their progression into pilot line work (2D-EPL) positions them as a potential bridge between graphene research and medical device manufacturing.

Highlights from their portfolio

• 2D-EPL
  Focused specifically on establishing an experimental pilot line for graphene, representing the critical transition from lab research to industrial production.
• GrapheneCore3
  Received EUR 1.87M in EC funding — MEDICA's largest funded contribution, indicating a significant role in this phase of the Flagship.